Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus

References

• Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875–1887. doi:10.1016/j.dsx.2020.09.026
   PubMed Web of Science ®Google Scholar
• Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273. doi:10.1001/jama.2015.5370
   PubMed Web of Science ®Google Scholar
• Ali A, Amin MJ, Ahmed MU, Taj A, Aasim M, Tabrez E. Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among type-2 diabetics. Pak J Med Sci. 2022;38(1):28–33. PMID: 35035396; PMCID: PMC8713246. doi:10.12669/pjms.38.1.4968
   PubMed Web of Science ®Google Scholar
• Koo SY, Park EJ, Lee CW. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med. 2020;52(8):1209–1219. PMID: 32770081; PMCID: PMC8080649. doi:10.1038/s12276-020-0480-3
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Zheng KI, Fan JG, Shi JP, et al. From NAFLD to MAFLD: a “redefining” moment for fatty liver disease. Chin Med J. 2020;133(19):2271–2273. doi:10.1097/cm9.0000000000000981
   PubMed Web of Science ®Google Scholar
• Yano K, Seko Y, Takahashi A, et al. Effect of sodium glucose cotransporter 2 inhibitors on renal function in patients with nonalcoholic fatty liver disease and type 2 diabetes in Japan. Diagnostics. 2020;10(2):86. doi:10.3390/diagnostics10020086
   Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161–2171.e5. doi:10.1016/j.cgh.2020.10.046
   PubMed Web of Science ®Google Scholar
• Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary Pancreat Dis Int. 2022;21(2):154–161. doi:10.1016/j.hbpd.2022.01.006
   PubMed Web of Science ®Google Scholar
• Zhou X, Lin X, Chen J, et al. Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity. Front Endocrinol. 2022;13:986841. PMID: 36120457; PMCID: PMC9471666. doi:10.3389/fendo.2022.986841
   PubMed Web of Science ®Google Scholar
• Zou Y, Zhong L, Hu C, Zhong M, Peng N, Sheng G. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. Lipids Health Dis. 2021;20(1):28. doi:10.1186/s12944-021-01457-1
   PubMed Web of Science ®Google Scholar
• Khamseh ME, Malek M, Abbasi R, Taheri H, Lahouti M, Alaei-Shahmiri F. Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metab Syndr Relat Disord. 2021;19(3):167–173. doi:10.1089/met.2020.0109
   PubMed Web of Science ®Google Scholar
• Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complications. 2021;35(5):107874. doi:10.1016/j.jdiacomp.2021.107874
   PubMed Web of Science ®Google Scholar
• Li N, Tan H, Xie A, et al. Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes. BMC Endocr Disord. 2022;22(1):101. doi:10.1186/s12902-022-00993-w
   PubMed Web of Science ®Google Scholar
• Health Management Branch of the Chinese Medical Association CNBotCNS, Association. NaMBotNHIEM. Expert consensus on the weight management process for overweight or obese individuals. Chin J Health Manag. 2021;15(4):317–322.
   Google Scholar
• Overweight/Obesity. ECWGoBQMPaPfCIPw. Expert consensus on body quality management pathways and processes for Chinese infertility patients with overweight/obesity. Chin J Reprod Contracept. 2020;40(12):965–971.
   Google Scholar
• Babic N, Valjevac A, Zaciragic A, Avdagic N, Zukic S, Hasic S. The triglyceride/HDL ratio and triglyceride glucose index as predictors of glycemic control in patients with diabetes mellitus type 2. Med Arch. 2019;73(3):163–168. doi:10.5455/medarh.2019.73.163-168
   PubMedGoogle Scholar
• Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a Cross-Sectional Retrospective Study. J Clin Med. 2021;10(2):346. PMID: 33477579; PMCID: PMC7831331. doi:10.3390/jcm10020346
   PubMed Web of Science ®Google Scholar
• Zeng J, Yang RX, Sun C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020;26(15):1792–1804. doi:10.3748/wjg.v26.i15.1792
   PubMed Web of Science ®Google Scholar
• Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis. 2020;21(7):372–384. doi:10.1111/1751-2980.12871
   PubMed Web of Science ®Google Scholar
• Yoo JJ, Kim W, Kim MY, et al. Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol. 2019;25(1):1–11. doi:10.3350/cmh.2018.0037
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications-Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
   Google Scholar
• Xing Y, Chen J, Liu J, Ma H. Associations between GGT/HDL and MAFLD: a Cross-Sectional Study. Diabetes Metab Syndr Obes. 2022;15:383–394. doi:10.2147/dmso.S342505
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–1393. doi:10.1210/er.2019-00034
   PubMed Web of Science ®Google Scholar
• Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. PMID: 34740573. doi:10.1016/j.metabol.2021.154925
   PubMed Web of Science ®Google Scholar
• Tarantino G, Balsano C, Santini SJ, et al. It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them? Int J Mol Sci. 2021;22(24):13424. PMID: 34948230; PMCID: PMC8706322. doi:10.3390/ijms222413424
   PubMed Web of Science ®Google Scholar
• Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci. 2023;24(7):6039. doi:10.3390/ijms24076039
   PubMed Web of Science ®Google Scholar
• Li L, Li Q, Huang W, et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021;12:589273. PMID: 34093169; PMCID: PMC8176308. doi:10.3389/fphar.2021.589273
   PubMed Web of Science ®Google Scholar
• Kim JA, Hwang SY, Yu JH, et al. Association of the triglyceride and glucose index with low muscle mass: KNHANES 2008–2011. Sci Rep. 2021;11(1):450. doi:10.1038/s41598-020-80305-1
   PubMed Web of Science ®Google Scholar
• Luo E, Wang D, Yan G, et al. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18(1):150. doi:10.1186/s12933-019-0957-3
   PubMed Web of Science ®Google Scholar
• Brody GH, Yu T, Chen E, Ehrlich KB, Miller GE. Racial discrimination, body mass index, and insulin resistance: a longitudinal analysis. Health Psychol. 2018;37(12):1107–1114. doi:10.1037/hea0000674
   PubMed Web of Science ®Google Scholar
• Malek M, Khamseh ME, Chehrehgosha H, Nobarani S, Alaei-Shahmiri F. Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. Endocrine. 2021;74(3):538–545. doi:10.1007/s12020-021-02815-w
   PubMed Web of Science ®Google Scholar
• Pal SC, Méndez-Sánchez N. Screening for MAFLD: who, when and how? Ther Adv Endocrinol Metab. 2023;14:20420188221145650. doi:10.1177/20420188221145650
   Web of Science ®Google Scholar
• Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis. 2021;17(1):23–28. doi:10.1002/cld.1045
   Google Scholar
• Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65–72. doi:10.1016/s2468-1253(20)30340-x
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390. doi:10.1016/s2468-1253(22)00062-0
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021;15(4):345–352. doi:10.1080/17474124.2021.1860019
   PubMed Web of Science ®Google Scholar